Stock Track | Atai Beckley Inc Soars 5.01% Intraday as Depression Drug Advances to Phase 3 Trials After Successful FDA Meeting

Stock Track03-10 22:45

Atai Beckley Inc's stock soared 5.01% during intraday trading on Tuesday, following the company's announcement that its experimental depression treatment is advancing to late-stage clinical trials.

The clinical-stage biotechnology company reported a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration for BPL-003 (mebufotenin benzoate nasal spray), clearing the path for Phase 3 initiation in the second quarter of 2026. BPL-003 holds Breakthrough Therapy Designation for treatment-resistant depression and demonstrated rapid antidepressant effects at Day 2 with durable improvements through eight weeks in Phase 2b studies.

Atai Beckley also reaffirmed its cash runway into early 2029, providing financial stability through the planned Phase 3 readouts. The company highlighted additional pipeline progress, including positive Phase 2a results for EMP-01 and expected Phase 2 topline data for VLS-01 in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment